Comparison

AbbVie Inc. (ABBV) vs Zoetis Inc. (ZTS)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ABBV

AbbVie Inc.

Drug Manufacturers—General

Revenue, FY25: $61.16B
Net income: $4.23B
Operating cash flow: $19.03B
Free cash flow: $17.82B
Net margin: 6.91%
Operating margin: 24.65%
Gross margin: 70.24%

ZTS

Zoetis Inc.

Drug Manufacturers—Specialty & Generic

Revenue, FY25: $9.47B
Net income: $2.67B
Operating cash flow: $2.9B
Free cash flow: $2.28B
Net margin: 28.23%
Operating margin: -
Gross margin: 71.84%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ABBV	ZTS
Revenue growth, latest filed year	+8.57%	+2.28%
Piotroski F-score	8 of 9	6 of 9
P/E against its own history	54.65% above	67.65% below

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ABBV

Reimbursement
Goodwill impairment
Litigation
Product recalls
FDA approval
Supply chain

And 16 more.

ZTS

Debt covenants
Tax
Cybersecurity
Litigation
Export controls
Goodwill impairment

And 19 more.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.06% · 0.09%

Updated Sep 3, 2026 · the newer of the two companies' filings